• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Friday's Pre-Market Session

    3/22/24 9:06:12 AM ET
    $BIOL
    $CUTR
    $ETON
    $GRFS
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $BIOL alert in real time by email

    Gainers

    • Biolase (NASDAQ:BIOL) shares moved upwards by 61.5% to $0.24 during Friday's pre-market session. The market value of their outstanding shares is at $4.6 million. The company's, Q4 earnings came out yesterday.
    • Outlook Therapeutics (NASDAQ:OTLK) shares moved upwards by 46.73% to $10.33. The market value of their outstanding shares is at $222.9 million.
    • Eton Pharmaceuticals (NASDAQ:ETON) shares rose 15.46% to $4.18. The market value of their outstanding shares is at $107.3 million.
    • Monogram Orthopaedics (NASDAQ:MGRM) stock moved upwards by 13.15% to $2.58. The market value of their outstanding shares is at $81.6 million.
    • Ontrak (NASDAQ:OTRK) shares increased by 11.49% to $0.29. The company's market cap stands at $7.9 million.
    • Nutriband (NASDAQ:NTRB) shares moved upwards by 10.16% to $2.71. The company's market cap stands at $22.9 million.

    Losers

    • SINTX Techs (NASDAQ:SINT) shares declined by 34.0% to $0.09 during Friday's pre-market session.
    • Cutera (NASDAQ:CUTR) shares fell 10.87% to $2.05. The company's market cap stands at $40.9 million. As per the press release, Q4 earnings came out yesterday.
    • Telesis Bio (NASDAQ:TBIO) stock decreased by 9.82% to $0.42. The market value of their outstanding shares is at $12.5 million.
    • Grifols (NASDAQ:GRFS) stock declined by 9.65% to $6.13. The market value of their outstanding shares is at $4.1 billion.
    • Yield10 Bioscience (NASDAQ:YTEN) stock fell 9.37% to $0.39. The market value of their outstanding shares is at $4.7 million.
    • Nkarta (NASDAQ:NKTX) shares decreased by 9.1% to $11.8. The company's market cap stands at $579.0 million. The company's, Q4 earnings came out yesterday. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $BIOL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BIOL
    $CUTR
    $ETON
    $GRFS

    CompanyDatePrice TargetRatingAnalyst
    Outlook Therapeutics Inc.
    $OTLK
    8/29/2025Buy → Neutral
    H.C. Wainwright
    Outlook Therapeutics Inc.
    $OTLK
    8/28/2025Buy → Neutral
    Guggenheim
    Nkarta Inc.
    $NKTX
    5/15/2025Outperform → Mkt Perform
    William Blair
    Grifols S.A.
    $GRFS
    2/12/2025Overweight
    Morgan Stanley
    Eton Pharmaceuticals Inc.
    $ETON
    1/23/2025$17.00 → $33.00Buy
    H.C. Wainwright
    Nutriband Inc.
    $NTRB
    1/22/2025$13.00Outperform
    Noble Capital Markets
    Eton Pharmaceuticals Inc.
    $ETON
    1/10/2025$21.00Buy
    B. Riley Securities
    Eton Pharmaceuticals Inc.
    $ETON
    1/6/2025$15.00 → $17.00Buy
    H.C. Wainwright
    More analyst ratings

    $BIOL
    $CUTR
    $ETON
    $GRFS
    SEC Filings

    View All

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    2/26/26 4:25:07 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Grifols S.A.

    6-K - Grifols SA (0001438569) (Filer)

    2/26/26 2:48:42 PM ET
    $GRFS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Eton Pharmaceuticals, Inc. (0001710340) (Filer)

    2/25/26 2:18:16 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nkarta to Participate in March Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the following investor conferences: March 2, 2026TD Cowen 46th Annual Health Care ConferenceBoston, MA9:10 a.m. EST – fireside chatMarch 10, 2026Leerink Global Healthcare ConferenceMiami, FL10:40 a.m. EDT – fireside chatA simultaneous webcast of both events will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biote

    2/27/26 8:00:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution

    DESMODA is the first and only FDA-approved desmopressin oral solutionCommercial launch expected on March 9thDESMODA eliminates tablet splitting and crushing, enabling precise, individualized dosing for patients of all agesThe product is expected to be a significant long-term growth contributor, with potential peak sales of $30-50 million annually and patent protection extending through 2044 DEER PARK, Ill., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or "the Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the U.S. Food and Drug Administration (FDA) approval of a Ne

    2/25/26 1:47:00 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

    DEER PARK, Ill., Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc ("Eton" or the "Company") (NASDAQ:ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that members of the Company's executive leadership team will host one-on-one meetings at the Leerink Partners Global Healthcare Conference on Wednesday, March 11, 2026 in Miami, Florida. To schedule a 1x1 meeting with the Company, please contact your Leerink Partners institutional sales representative. About Eton PharmaceuticalsEton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Co

    2/20/26 6:50:00 AM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Outlook Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Outlook Therapeutics from Buy to Neutral

    8/29/25 8:20:01 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Outlook Therapeutics downgraded by Guggenheim

    Guggenheim downgraded Outlook Therapeutics from Buy to Neutral

    8/28/25 12:48:22 PM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nkarta downgraded by William Blair

    William Blair downgraded Nkarta from Outperform to Mkt Perform

    5/15/25 8:09:11 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Chief Investment Officer Honigblum Gregg R. bought $34,896 worth of shares (8,200 units at $4.26), increasing direct ownership by 4% to 201,067 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    12/9/25 8:00:05 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Moyes Jay M bought $2,910 worth of shares (1,000 units at $2.91), increasing direct ownership by 33% to 4,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/25/26 9:00:02 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Director Anderson Mark Lewis bought $9,060 worth of shares (3,000 units at $3.02), increasing direct ownership by 20% to 18,000 units (SEC Form 4)

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/19/26 9:00:04 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Chief Financial Officer Trask Kevin

    4 - Sintx Technologies, Inc. (0001269026) (Issuer)

    2/10/26 8:45:54 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Leadership Updates

    Live Leadership Updates

    View All

    SINTX Technologies Appoints Ryan Elmore President to Lead Channel Expansion of Silicon Nitride Biomaterial Platforms

    Appointment supports acceleration of revenue opportunities from SiNERGY™ silicon nitride devices and antipathogenic fibrous material technologies SALT LAKE CITY, Utah, Feb. 18, 2026 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon nitride (SiN) solutions for medical and other high-value applications, today announced the appointment of Ryan Elmore as President of SINTX Technologies, Inc., effective March 16, 2026. Mr. Elmore most recently served as Core Business Director at Invibio, a division of Victrex plc. With more than 15 years of experience in advanced biomaterials and medical dev

    2/18/26 8:30:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    Outlook Therapeutics Appoints Laura Cantrell as Vice President of Corporate Strategy and Business Development

    ISELIN, N.J., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced it has appointed Laura Cantrell as Vice President of Corporate Strategy and Business Development. "We are very pleased to welcome Laura to Outlook Therapeutics at such a pivotal time in our evolution," said Bob Jahr, Chief Executive Officer of Outlook Therapeutics. "Laura's two decades of global biotechnology experience spanning corporate strategy, business development and portfolio leadership, and her proven ability to identify, evaluate and execute high-value

    1/6/26 8:35:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Nutriband Inc. to Present on the Emerging Growth Conference on August 20, 2025

    ORLANDO, Fla., Aug. 18, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (the "Company") is pleased to announce that it has been invited to present on the Emerging Growth Conference on August 20, 2025. The next Emerging Growth Conference is presenting on August 20, 2025. This live, interactive online event will give existing shareholders and the investment community the opportunity to interact with the Company's Chairman, Serguei Melnik in real time. Mr. Melnik will perform a presentation and may subsequently open the floor for questions. Please submit your questions in advance to [email protected] or ask your questions during the event and Mr. Melnik will do his best to

    8/18/25 9:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Financials

    Live finance-specific insights

    View All

    Nutriband CEO Publishes Letter to Shareholders

    ORLANDO, Fla., Dec. 31, 2025 (GLOBE NEWSWIRE) -- Nutriband Inc. (NASDAQ:NTRB) (NASDAQ:NTRBW) today announced that CEO Gareth Sheridan has published a letter to shareholders providing insights on achievements and milestones through 2025 and the potential outlook for 2026. The full text of the letter is below. Dear Shareholders, As we wrapped up a successful 2025, the entire team at Nutriband would like to extend our warmest appreciation to all of you for your continued support throughout 2025 and into 2026. I always stress and extend our appreciation to the many of you that have been with us from the beginning and now the many more who have joined our common goal along the way. This goal

    12/31/25 7:00:00 AM ET
    $NTRB
    Industrial Specialties
    Health Care

    Outlook Therapeutics Reports Financial Results for Fiscal Year 2025

    ISELIN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced financial results for fiscal year 2025. Financial Highlights for the Fiscal Year Ended September 30, 2025 For the fiscal year ended September 30, 2025, Outlook Therapeutics reported net loss attributable to common stockholders of $62.4 million, or $1.79 per basic and diluted share, and $1.4 million of revenue. This compares with net loss attributable to common stockholders of $75.4 million, or $4.06 per basic and diluted share, and no revenue for the prior year.

    12/19/25 8:05:00 AM ET
    $OTLK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SINTX Reports Pivotal Third Quarter Business Update and Financial Highlights Driven by FDA Clearance, Product and IP Portfolio Expansions and Increased Operational Efficiencies

    Company underscores its strengthened liquidity, cost reductions, and first revenue recorded from OsseoSculpt™  SALT LAKE CITY, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ:SINT) ("SINTX" or the "Company"), an advanced ceramics and biomaterials company focused on silicon-nitride–based medical technologies, today provided a business update reporting third quarter financial results in conjunction with the filing the Company's Form 10-Q for the quarter ended September 30, 2025. During the third quarter and subsequent weeks, SINTX advanced a focused commercialization plan centered on infection-resistant silicon nitride devices and polymer composites, while tighteni

    11/13/25 8:00:00 AM ET
    $SINT
    Medical/Dental Instruments
    Health Care

    $BIOL
    $CUTR
    $ETON
    $GRFS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Eton Pharmaceuticals Inc.

    SC 13G - Eton Pharmaceuticals, Inc. (0001710340) (Subject)

    12/9/24 4:04:43 PM ET
    $ETON
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by SiNtx Technologies Inc.

    SC 13G/A - Sintx Technologies, Inc. (0001269026) (Subject)

    11/14/24 7:25:52 PM ET
    $SINT
    Medical/Dental Instruments
    Health Care